Search Results - "Sayala, Hazem"

Rituximab Plus Chlorambucil As First-Line Treatment for Chronic Lymphocytic Leukemia: Final Analysis of an Open-Label Phase II Study by HILLMEN, Peter, GRIBBEN, John G, NATHWANI, Amit, VARGHESE, Abraham, COHEN, Dena, RAWSTRON, Andy, OERTEL, Stephan, POCOCK, Christopher F. E, FOLLOWS, George A, MILLIGAN, Donald, SAYALA, Hazem A, MORETON, Paul, OSCIER, David G, DEARDEN, Claire E, KENNEDY, Daniel B, PETTITT, Andrew R

“…Most patients with chronic lymphocytic leukemia (CLL) are elderly and/or have comorbidities that may make them ineligible for fludarabine-based treatment. For…”
Get full text

A randomized phase II trial of fludarabine, cyclophosphamide and mitoxantrone (FCM) with or without rituximab in previously treated chronic lymphocytic leukaemia by Hillmen, Peter, Cohen, Dena R., Cocks, Kim, Pettitt, Andrew, Sayala, Hazem A., Rawstron, Andy C., Kennedy, Daniel B., Fegan, Christopher, Milligan, Don W., Radford, John, Mercieca, Jane, Dearden, Claire, Ezekwisili, Raphael, Smith, Alexandra F., Brown, Julia, Booth, Gillian A., Varghese, Abraham M., Pocock, Christopher

“…Summary Combination fludarabine (F), cyclophosphamide (C) and rituximab (R) is the standard front‐line therapy in chronic lymphocytic leukaemia (CLL), but…”
Get full text

Minimal residual disease assessment in chronic lymphocytic leukaemia by Sayala, Hazem A., MRCP(UK), Rawstron, Andy C., PhD, Hillmen, Peter, MD, PhD

“…The concept of minimal residual disease (MRD) eradication in chronic lymphocytic leukaemia (CLL) is a relatively new one, as conventional therapy with…”
Get full text

Skeletal-Related Events In Myeloma: A Population-Based Study by Ashcroft, John, Timothy, Bagguley, Smith, Alexandra, Wang, Han-I, Howell, Debra, Sayala, Hazem A, Cook, Gordon, Jack, Andrew, Patmore, Russell, Roman, Eve

“…New therapies have resulted in improvements in myeloma survival, with increasing numbers of patients receiving treatment over several years. Despite this…”
Get full text

Rituximab Plus Chlorambucil In Patients with CD20-Positive B-Cell Chronic Lymphocytic Leukemia (CLL): Final Response Analysis of An Open-Label Phase II Study by Hillmen, Peter, Gribben, John G., Follows, George A., Milligan, Donald, Sayala, Hazem A., Moreton, Paul, Oscier, David G., Dearden, Claire E., Kennedy, Daniel B., Pettitt, Andrew R., Nathwani, Amit, Cohen, Dena, Rawstron, Andy, Pocock, Christopher F.E.

“…Abstract 697 Despite the increasing use of combination therapy with rituximab, fludarabine and cyclophosphamide (R-FC) for chronic lymphocytic leukemia (CLL),…”
Get full text

Long Term Survival Report of the UKCLL02 Trial: A Phase II Study of Subcutaneous Alemtuzumab In Patients with Fludarabine Refractory CLL (on Behalf of the NCRI CLL Trials Sub-Group) by Varghese, Abraham M, Sayala, Hazem A., Moreton, Paul, Jones, Richard A, Rawstron, Andy, Sheila, J, Evans, Paul, Anthony, Carter, Dearden, Claire E., Matutes, Estella, Pettitt, Andrew R., Kennedy, Daniel B., Barrans, Sharon, Worrillow, Lisa, Hillmen, Peter

“…Abstract 922 Patients with fludarabine refractory chronic lymphocytic leukemia (CLL) have a very poor prognosis with conventional chemotherapy with a median…”
Get full text

An Open-Label Phase II Study to Investigate the Safety and Efficacy of Rituximab Plus Chlorambucil in Previously Untreated Patients with CD20-Positive B-Cell Chronic Lymphocytic Leukaemia (CLL) by Hillmen, Peter, Gribben, John G., Follows, George A, Milligan, Donald W., Sayala, Hazem A., Moreton, Paul, Oscier, David, Dearden, Claire E., Kennedy, Daniel B., Pettitt, Andrew R., Nathwani, Amit, Cohen, Dena, Gregory, Walter M, Rawstron, Andy C., Hayward, Colin R.W., Pocock, Christopher

“…Abstract 3428 Poster Board III-316 Despite the increasing use of fludarabine (F) plus cyclophosphamide (C), and recently rituximab (R)-FC combinations in CLL,…”
Get full text

Eradication of Minimal Residual Disease with Alemtuzumab in Chronic Lymphocytic Leukemia Is Associated with Prolonged Survival and Is an Appropriate Theraputic Endpoint for Relapsed CLL by Sayala, Hazem A., Moreton, Paul, Kennedy, Ben, Lucas, Guy, Leach, Michael, Rassam, Saad M.B., Haynes, Andrew, Tighe, Jane, Oscier, David G., Fegan, Christopher, Rawstron, Andy C., Hillmen, Peter

“…Eradication of minimal residual disease (MRD) in chronic lymphocytic leukemia (CLL) is emerging as a desirable therapeutic end point predicting for better…”
Get full text

EBV Related Transformation Events in CLL by Sayala, Hazem A., O'Connor, Sheila J., Jack, Andrew S., Patalappa, Chetan, Hillmen, Peter, Owen, Roger G.

“…Less than 5% of patients with CLL undergo histological transformation to diffuse large B cell lymphoma (DLBL) while transformation to Classical Hodgkins…”
Get full text

NCRI CLL201 Trial: A Randomized Phase II Trial of Fludarabine, Cyclophosphamide and Mitoxantrone (FCM) with or without Rituximab in Previously Treated CLL by Hillmen, Peter, Pocock, Christopher, Cohen, Dena, Cocks, Kim, Sayala, Hazem A., Rawstron, Andy, Kennedy, Daniel B., Fegan, Christopher, Milligan, Don W., Dearden, Claire, Smith, Alexandra, Lindop, Emma, Pettitt, Andrew R.

“…Standard front-line therapy for chronic lymphocytic leukemia (CLL) is fludarabine plus cyclophosphamide. Adding mitoxantrone (FCM) or rituximab (FCR) appears…”
Get full text

Development of EBV-associated diffuse large B-cell lymphoma in Waldenström macroglobulinemia and mantle cell lymphoma by Varghese, Abraham M., Sayala, Hazem, Evans, Paul A. S., O'Connor, Sheila J. M., Patmore, Russell, Hillmen, Peter, Owen, Roger G.

Get full text

Final Report of the UKCLL02 Trial: A Phase II Study of Subcutaneous Alemtuzumab Plus Fludarabine in Patients with Fludarabine Refractory CLL (on Behalf of the NCRI CLL Trials Sub-Group) by Sayala, Hazem A., Moreton, Paul, Jones, Richard A., Rawstron, Andy C., O'Connor, Sheila J., Evans, Paul, Anthony, Carter, Dearden, Claire, Matutes, Estella, Pettitt, Andrew R., Kennedy, Daniel B., Hillmen, Peter

“…Patients with fludarabine refractory CLL have a median survival of 10 months with conventional chemotherapy. Intravenous (IV) alemtuzumab results in 33 to 50%…”
Get full text

Bi-Allelic Deletion of 13q14 Is Associated with Inferior Progression Free Survival Compared to Mono-Allelic 13q14 Deletion in B-Cell Chronic Lymphocytic Leukaemia by O'Connor, Sheila J., Turner, Kathryn, Barrans, Sharon L., Dickinson, Brad, Rawstron, Andy C., Sayala, Hazem, Moreton, Paul, Owen, Roger G., Jack, Andrew S., Hillmen, Peter

“…Isolated mono-allelic deletion of chromosome region 13q14 is seen in 40–60% of patients with typical B-CLL and is associated with good risk disease. Bi-allelic…”
Get full text

Interim Report of the UKCLL02 Trial: A Phase II Study of Subcutaneous Alemtuzumab Plus Fludarabine in Patients with Fludarabine Refractory CLL (on Behalf of the NCRI CLL Trials Sub-Group) by Sayala, Hazem, Moreton, Paul, Richard, Jones A., Andy, Rawstron C., Sheila, O'Connor, Paul, Evans, Anthony, Carter, Claire, Dearden, Estella, Matutes, Andrew, Pettitt R., Daniel, Kennedy B., Peter, Hillmen

“…Patients with fludarabine refractory CLL have a median survival of 10 months with conventional chemotherapy. Intravenous (IV) alemtuzumab is approved in…”
Get full text

Development of EBV-associated diffuse large B-cell lymphoma in Waldenstrom macroglobulinemia and mantle cell lymphoma by Varghese, Abraham M, Sayala, Hazem, Evans, Paul A S, O'Connor, Sheila J M, Patmore, Russell, Hillmen, Peter, Owen, Roger G

Get full text